Fate Therapeutics, Inc. (FATE) is a publicly traded Healthcare sector company. As of October 12, 2026, FATE trades at $2.19 with a market cap of $261.21M and a P/E ratio of -2.12. FATE moved +0.64% today. Year to date, FATE is +121.86%; over the trailing twelve months it is +35.40%. Its 52-week range spans $0.66 to $3.23. Analyst consensus is buy with an average price target of $6.63. Rallies surfaces FATE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for FATE combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $2.19 |
| Market Cap | $261.21M |
| P/E Ratio | -2.12 |
| EPS | $-1.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.23 |
| 52-Week Low | $0.66 |
| Volume | 232 |
| Avg Volume | 0 |
| Revenue (TTM) | $6.49M |
| Net Income | $-126.00M |
| Gross Margin | 0.00% |
6 analysts cover FATE: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.63.